基本信息
浏览量:35
职业迁徙
个人简介
After finishing my Pharmacy degree at the University of Valencia in 2001, I completed my studies at the University of Navarra with a Master in “Research and Development of New Drugs”. Driven by my interest in drug discovery, I then started working in the pharmaceutical industry (Idifarma, Lacer, Almirall), gaining experience in different areas related to drug discovery and development, such as analytical technique development, quality control, and regulatory affairs. In 2010, I joined the Structural Biochemistry Laboratory (SBL) at the Centro de Investigación Principe Felipe (CIPF), to pursue my PhD Thesis entitled “NMR applications for the identification of new clinically relevant biomarkers in the oncology area”. Profiting from my previous experience in the pharmaceutical industry, since joining the SBL, I was able to contribute to a number of drug discovery projects, carried out in collaboration with big pharmaceutical companies, focused on fragment-based screening approaches for identifying novel inhibitors against pharmaceutically relevant targets. Additionally, I have been leading different clinical metabolomics projects aimed at identifying clinical biomarkers for early diagnosis and treatment monitoring of patients, and have actively participated in the development of all the metabolomics protocols currently available at that laboratory. As a postdoctoral researcher, I became extremely interested in the development of integrative approaches that could lead to the identification of new potential drug targets. During my postdoctoral research period I have performed different research stages in the Hemato- oncology Program at the Centre for Applied Medical Research (CIMA, Pamplona, Spain) and the Signalling & Cancer Metabolism group, at the Institute of Cancer Research (ICR, London). Following my interest in gaining a deeper understanding of the biological processes underlying cancer progression, I was awarded an EMBO short-term fellowship (3 months) in 2017 and a Jose Castillejo fellowship from the Spanish Ministry of Science and Education (6 months) in 2018 that allowed me to join the Signalling & Cancer Metabolism group, at the Institute of Cancer Research (ICR, London). Subsequently, in 2018, I joined the lab as a post-doctoral training fellow. During that time, I have focused on the application and development of integrative analysis tools, based on a combination of cell biology, biochemical, functional screening, transcriptomics and metabolomics data obtained from the analysis of clinical samples and experimental models. More recently, I have been awarded a Miguel Servet research contract from the Health Institute Carlos III (Spain) to establish my own line of research. My current research line perfectly integrates my research interests and my scientific background in nuclear magnetic resonance (NMR), metabolomics, bioinformatics and drug discovery, while leveraging the research expertise on cancer metabolism and signalling I have gained during my postdoctoral research. Currently, I lead the Drug Discovery Unit at the IIS La Fe and act as Scientific Coordinator of the Strategy on Innovative and Precision Medicines sponsored by the Conselleria de Sanidad Universal y Salud Pública, Generalitat Valenciana and the European Regional Development Fund (FEDER) funds (PO FEDER of Comunitat Valenciana 2014‐2020).
研究兴趣
论文共 39 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Marta Garrido-Jareño,José Miguel Sahuquillo-Arce, Héctor Rodríguez-Vega,Carmen Lloret-Sos,Ana Gil-Brusola,José Luis López-Hontangas,María Nuñez-Beltran,Jordi Tortosa-Carreres,José Ángel García-García,Lourdes Cordón,Leonor Puchades-Carrasco, Carmen Carreras-Gil de Santivañes,
Rita C Acúrcio,Sabina Pozzi,Barbara Carreira,Marta Pojo,Nuria Gómez-Cebrián,Sandra Casimiro,Adelaide Fernandes,Andreia Barateiro, Vitor Farricha, Joaquim Brito,Ana Paula Leandro,Jorge A R Salvador,
Biomedical journalno. 4 (2021): 654-664
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn